Background: personalized approach considering the effectiveness and safety of the medication is the main goal of contemporary psychopharmacotherapy. Knowing special characteristics of any given drug allows a practitioner to choose the tactic meeting needs of the particular patient.The aim of this narrative review was to summarize the data about use Brexpiprazole of in pharmacotherapy of different mental disorders.Method: using the keywords “brexpiprazole”, “psychoses”, “treatment” we performed a scientific publications search in PubMed and PsychInfo databases over the last 10 years.Results: brexpiprazole is supposed to resemble such third generation antypsychotics as aripiprazole and cariprazine, lacking their drawbacks. There is a history of using brexpiprazole in schizophrenia and unipolar depression. Pilot studies and clinical cases were presented on the possible perspectives in use of brexpiprazole, such as Alzheimer disease, posttraumatic stress disorder, borderline personality disorder and bipolar affective disorder. On the basis of the reviewed data we conclude that brexpiprazole is effective for cupping and maintenance treatment of schizophrenia, for augmentation in recurrent depressive disorder and is also perspective in other fields of psychiatry. Brexpiprazole has a favorable safety profile with low incidence of metabolic, extrapyramidal and hyperstimulation symptoms.
Background: Aripiprazole, among other atypical antipsychotics, is recommended as a drug for maintenance therapy in schizophrenia in cases in which the patient is identified as having depressive symptoms. At the same time, depression in schizophrenia is not listed as a separate indication for Aripiprazole, its antidepressant properties are considered only in the recommendations for the treatment of bipolar depression and augmentation of antidepressant therapy in recurrent depressive disorder. There are no works characterizing the efficacy of the drug in depression in patients with schizophrenia, as well as evaluating the spectrum of its antidepressant action in such conditions.Objective of the study: to examine the therapeutic efficacy and safety of Aripiprazole (Zylaxera®) in the augmentation therapy of moderate to severe depressive states in patients with schizophrenia.Patients and methods: the efficacy and safety of Aripiprazole (Zylaxera®) augmentation therapy with 5–20 mg daily dose for 6 weeks was studied in 72 patients aged 18 to 47 years (all women) with depressive states of at least 17 Hamilton Scale scores in remitted schizophrenia, postchizophrenic depression and schizotypal disorder (F20.01 + F32.1–2; F20.04; F21.3–4 + F32.1–2). The HDRS-21, CGI, and UKU scales were used for psychometric assessment.Results: the effectiveness of augmentation of antidepressant therapy with Zylaxera® was revealed in the majority of patients: the rate of responders as evaluated by the HDRS-21 scale (reduction of severity of depressive disorders by 50% or more) was 67.2% and 71.4% for the CGI scale. At the same time, it was established that the group of responders had a certain similarity in terms of psychopathological structure of depressive states.Conclusion: it has been established, that in patients suffering from schizophrenia Zylaxera® has a distinct efficacy in augmentation of antidepressant therapy and has a favorable tolerability profile. The maximum efficacy of the drug within the framework of such use is observed in depressive states with predominance of negative affectivity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.